ストックスクリーナーアプリを入手
60.23
3.10%
1.81
アフターアワーズ：
60.34
0.11
+0.18%
前日終値:
$58.42
開ける：
$58.5
24時間の取引高:
5.45M
Relative Volume:
0.86
時価総額：
$23.49B
収益：
$4.30B
当期純損益:
$571.50M
株価収益率:
42.16
EPS:
1.4285
ネットキャッシュフロー:
$570.80M
1週間 パフォーマンス:
+3.74%
1か月 パフォーマンス:
-13.65%
6か月 パフォーマンス:
-29.05%
1年 パフォーマンス:
-19.11%
1日の値動き範囲:
$58.35
$61.15
1週間の範囲:
$57.20
$61.15
52週間の値動き範囲:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
DXCM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
60.23 | 22.78B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 再開されました | Stifel | Buy |
| 2025-09-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 開始されました | Argus | Buy |
| 2025-06-16 | 開始されました | Truist | Buy |
| 2025-05-30 | 開始されました | Goldman | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
| 2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2023-01-26 | 開始されました | Wolfe Research | Outperform |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-15 | 開始されました | Bernstein | Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2021-01-06 | アップグレード | UBS | Neutral → Buy |
| 2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
| 2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-10-23 | 開始されました | Stifel | Buy |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
| 2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-04 | 開始されました | Goldman | Sell |
| 2018-04-04 | 開始されました | Guggenheim | Neutral |
| 2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
DXCM Announcement: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (DXCM) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit - PR Newswire
Bank Julius Baer & Co. Ltd Zurich Sells 8,697 Shares of DexCom, Inc. $DXCM - Defense World
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Yahoo Finance
Top 2 Healthcare Stocks Every New Investor Should Know - The Motley Fool
DexCom, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsDXCM - MarketScreener
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
DexCom Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages DexCom, Inc. - GlobeNewswire
DCXM DEADLINE ALERT: DexCom, Inc. Investors Urged to Contact Kirby McInerney LLP About Class Action Lawsuit - GlobeNewswire
Dexcom (DXCM) Valuation: Assessing Upside After FDA Clearance of Smart Basal Diabetes Device - Yahoo Finance Singapore
Levi & Korsinsky Notifies Shareholders of DexCom, Inc. (DXCM) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewswire
Dexcom Smart Basal Receives FDA Clearance for Personalized Basal Insulin Dosing - Pharmacy Times
DXCM Deadline Alert: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
Dexcom to Release G7 15 Day CGM Next Month - Medical Product Outsourcing
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States - GuruFocus
Dexcom G7 15 day continuous glucose monitoring system to launch on Dec. 1 in the United States - MarketScreener
Dexcom G7 15 Day Continuous Glucose Monitoring System To Launch On Dec. 1 In The United States - TradingView
The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025DXCM - PR Newswire
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal - Zacks Investment Research
Is DexCom Inc. (DC4) stock cheap by valuation metricsQuarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com
FDA clearances: Dexcom, GE HealthCare, Zimmer Biomet, BrainsWay - Modern Healthcare News
DexCom, Inc. $DXCM Shares Acquired by Artisan Partners Limited Partnership - Defense World
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - MarketScreener
Will DexCom Inc. (DC4) stock profit from AI boomWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Can DexCom Inc. (DC4) stock sustain revenue momentumOil Prices & Long-Term Growth Stock Strategies - newser.com
Bragar Eagel & Squire, P.C. Urges Stockholders of DexCom, - GlobeNewswire
FDA clears Dexcom Smart Basal for insulin optimization - BioWorld MedTech
The Gross Law Firm Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming ... - Bluefield Daily Telegraph
The Gross Law Firm Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – DXCM - GlobeNewswire
Dexcom Smart Basal wins FDA Clearance for Type 2 diabetes insulin support - Medical Economics
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
FDA OKs Dexcom’s Insulin Dosing Optimizer for Type 2 Diabetes - Medical Product Outsourcing
DexCom Receives US FDA Approval for Insulin Dosing Optimizer - MarketScreener
Will DexCom Inc. (DC4) stock keep high P E multiplesQuarterly Portfolio Report & Real-Time Market Sentiment Reports - newser.com
DexCom (DXCM) Gains FDA Approval for Smart Basal Insulin Dosing Optimizer - GuruFocus
Dexcom Smart Basal Receives FDA Clearance Becoming the First and - GuruFocus
Dexcom receives FDA clearance for first CGM-integrated basal insulin optimizer By Investing.com - Investing.com South Africa
Dexcom wins FDA nod for smart CGM-integrated basal dosing for type 2 diabetes - MassDevice
Dexcom smart basal receives FDA clearance becoming the first and only CGM-integrated basal insulin dosing optimizer for type 2 diabetes - MarketScreener
Dexcom receives FDA clearance for first CGM-integrated basal insulin optimizer - Investing.com Australia
Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes - DexCom Investor Relations
Is DexCom Inc. stock a bargain at current levelsJuly 2025 Market Mood & Proven Capital Preservation Methods - newser.com
DexCom Inc. stock outlook for YEAREarnings Recap Report & Fast Entry Momentum Alerts - newser.com
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - NewMediaWire
Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations - Nasdaq
Alberta Investment Management Corp Has $450,000 Position in DexCom, Inc. $DXCM - Defense World
DexCom (DXCM) eyes deeper correction toward $44.11–$20.95 zone - FXStreet
Dexcom Wrongful Death Lawsuit Alleges Continuous Glucose Monitor Failed - AboutLawsuits.com
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Morningstar
Join Class Action to Recover Losses from DexCom, Inc. (DXCM)Contact Levi & Korsinsky Before December 26, 2025 - ACCESS Newswire
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
5.84%
大文字化:
|
ボリューム (24 時間):